DSpace Repository

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

Show simple item record

dc.contributor.author Lewczuk, Piotr
dc.contributor.author Riederer, Peter
dc.contributor.author O'Bryant, Sid E.
dc.contributor.author Verbeek, Marcel M.
dc.contributor.author Dubois, Bruno
dc.contributor.author Visser, Pieter Jelle
dc.contributor.author Jellinger, Kurt A.
dc.contributor.author Engelborghs, Sebastiaan
dc.contributor.author Ramirez, Alfredo
dc.contributor.author Parnetti, Lucilla
dc.contributor.author Jack, Clifford R.
dc.contributor.author Teunissen, Charlotte E.
dc.contributor.author Hampel, Harald
dc.contributor.author Lleó, Alberto
dc.contributor.author Jessen, Frank
dc.contributor.author Glodzik, Lidia
dc.contributor.author de Leon, Mony J.
dc.contributor.author Fagan, Anne M.
dc.contributor.author Molinuevo, José Luis
dc.contributor.author Jansen, Willemijn J.
dc.contributor.author Winblad, Bengt
dc.contributor.author Shaw, Leslie M.
dc.contributor.author Andreasson, Ulf
dc.contributor.author Otto, Markus
dc.contributor.author Mollenhauer, Brit
dc.contributor.author Wiltfang, Jens
dc.contributor.author Turner, Martin R.
dc.contributor.author Zerr, Inga
dc.contributor.author Handels, Ron
dc.contributor.author Thompson, Alexander G.
dc.contributor.author Johansson, Gunilla
dc.contributor.author Ermann, Natalia
dc.contributor.author Trojanowski, John Q.
dc.contributor.author Karaca, Ilker
dc.contributor.author Wagner, Holger
dc.contributor.author Oeckl, Patrick
dc.contributor.author van Waalwijk van Doorn, Linda
dc.contributor.author Bjerke, Maria
dc.contributor.author Kapogiannis, Dimitrios
dc.contributor.author Kuiperij, H. Bea
dc.contributor.author Farotti, Lucia
dc.contributor.author Li, Yi
dc.contributor.author Gordon, Brian A.
dc.contributor.author Epelbaum, Stéphane
dc.contributor.author Vos, Stephanie J. B.
dc.contributor.author Klijn, Catharina J. M.
dc.contributor.author Van Nostrand, William E.
dc.contributor.author Minguillon, Carolina
dc.contributor.author Schmitz, Matthias
dc.contributor.author Gallo López-Aliaga, Carla Maria
dc.contributor.author Lopez Mato, Andrea
dc.contributor.author Thibaut, Florence
dc.contributor.author Lista, Simone
dc.contributor.author Alcolea, Daniel
dc.contributor.author Zetterberg, Henrik
dc.contributor.author Blennow, Kaj
dc.contributor.author Kornhuber, Johannes
dc.contributor.author WFSBP Task Force
dc.date.accessioned 2018-11-30T02:09:31Z
dc.date.available 2018-11-30T02:09:31Z
dc.date.issued 2018
dc.identifier.uri https://hdl.handle.net/20.500.12866/4020
dc.description.abstract In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer's disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, biobanking, analyses and post-analytical interpretation of the results were intensively studied and optimised. A global quality control project was introduced to evaluate and monitor the inter-centre variability in measurements with the goal of harmonisation of results. Contexts of use and how to approach candidate biomarkers in biological specimens other than cerebrospinal fluid (CSF), e.g. blood, were precisely defined. Important development was achieved in neuroimaging techniques, including studies comparing amyloid-β positron emission tomography results to fluid-based modalities. Similarly, development in research laboratory technologies, such as ultra-sensitive methods, raises our hopes to further improve analytical and diagnostic accuracy of classic and novel candidate biomarkers. Synergistically, advancement in clinical trials of anti-dementia therapies energises and motivates the efforts to find and optimise the most reliable early diagnostic modalities. Finally, the first studies were published addressing the potential of cost-effectiveness of the biomarkers-based diagnosis of neurodegenerative disorders. en_US
dc.language.iso eng
dc.publisher Taylor and Francis
dc.relation.ispartofseries World Journal of Biological Psychiatry
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Humans en_US
dc.subject Societies, Medical en_US
dc.subject Biomarkers en_US
dc.subject Consensus en_US
dc.subject Alzheimer’s disease en_US
dc.subject Biological Psychiatry en_US
dc.subject biomarkers en_US
dc.subject cerebrospinal fluid en_US
dc.subject consensus en_US
dc.subject dementia en_US
dc.subject Dementia en_US
dc.subject Neurodegenerative Diseases en_US
dc.title Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1080/15622975.2017.1375556
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.24
dc.relation.issn 1814-1412

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


My Account